Intellia Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Intellia Therapeutics
NTLA Stock  USD 13.89  0.07  0.51%   
Intellia Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Intellia Therapeutics' valuation are provided below:
Gross Profit
-352.4 M
Market Capitalization
1.7 B
Enterprise Value Revenue
20.9072
Revenue
57.5 M
Earnings Share
(4.25)
We have found one hundred twenty available fundamental trends for Intellia Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Intellia Therapeutics regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

Intellia Therapeutics Total Revenue

35.95 Million

Check Intellia Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intellia Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.4 M, Interest Expense of 10.3 M or Selling General Administrative of 151.9 M, as well as many indicators such as Price To Sales Ratio of 17.03, Dividend Yield of 0.0 or PTB Ratio of 1.44. Intellia financial statements analysis is a perfect complement when working with Intellia Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Intellia Stock
Check out the analysis of Intellia Therapeutics Correlation against competitors.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.

Intellia Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets743.3 M1.4 B564 M
Slightly volatile
Other Current Liabilities66.8 M63.7 M25.5 M
Slightly volatile
Total Current Liabilities69.4 M127.5 M53 M
Slightly volatile
Total Stockholder Equity585.8 M1 B439.8 M
Slightly volatile
Other Liabilities38.1 M50.6 M28.9 M
Slightly volatile
Property Plant And Equipment Net297.9 M283.7 M81 M
Slightly volatile
Accounts Payable17.6 M16.8 M5.7 M
Slightly volatile
Cash203.8 M217.6 M147 M
Slightly volatile
Non Current Assets Total665.5 M633.8 M185.6 M
Slightly volatile
Non Currrent Assets Other314.2 M299.2 M78.9 M
Slightly volatile
Other Assets19 M18.1 M7 M
Slightly volatile
Cash And Short Term Investments534.6 M691.7 M388.9 M
Slightly volatile
Common Stock Total Equity7.7 K8.1 K197.8 K
Slightly volatile
Common Stock Shares Outstanding58 M113.7 M46.7 M
Slightly volatile
Liabilities And Stockholders Equity743.3 M1.4 B564 M
Slightly volatile
Non Current Liabilities Total251.4 M239.4 M80.8 M
Slightly volatile
Other Current Assets36 M34.3 M13.6 M
Slightly volatile
Other Stockholder Equity3.7 B3.5 B1.2 B
Slightly volatile
Total Liabilities385.3 M366.9 M137.6 M
Slightly volatile
Property Plant And Equipment Gross357.9 M340.8 M96.6 M
Slightly volatile
Total Current Assets557.9 M735.8 M406.7 M
Slightly volatile
Common Stock8.6 K9 K198 K
Slightly volatile
Property Plant Equipment18.1 M32.1 M15 M
Slightly volatile
Current Deferred Revenue28.7 M23.8 M20.3 M
Slightly volatile
Net Receivables9.1 M9.8 M6.3 M
Slightly volatile
Capital Surpluse2.9 B2.8 B1 B
Slightly volatile
Deferred Long Term Liabilities38.9 M50.7 M30.8 M
Slightly volatile
Non Current Liabilities Other29 M27.6 M11.9 M
Slightly volatile
Net Invested Capital766.3 M1 B555.7 M
Slightly volatile
Net Working Capital627 M608.4 M474.1 M
Slightly volatile
Capital Stock8.2 K11.5 K6.6 K
Slightly volatile
Short and Long Term Debt Total253.8 M241.7 M73.5 M
Slightly volatile
Capital Lease Obligations253.8 M241.7 M73.5 M
Slightly volatile
Long Term Investments189.9 M350.2 M95.2 M
Slightly volatile
Short Term Debt13.9 M23.3 M9.7 M
Slightly volatile

Intellia Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization12.4 M11.8 M4.6 M
Slightly volatile
Selling General Administrative151.9 M144.7 M52.3 M
Slightly volatile
Other Operating Expenses715 M681 M238.3 M
Slightly volatile
Research Development563.1 M536.3 M186 M
Slightly volatile
Cost Of Revenue8.8 M9.3 M30.5 M
Pretty Stable
Total Operating Expenses702.6 M669.1 M228.5 M
Slightly volatile
Net Interest Income57.7 M55 M14.2 M
Slightly volatile
Interest Income57.7 M55 M14.2 M
Slightly volatile
Reconciled Depreciation7.3 M11.8 M5.5 M
Slightly volatile

Intellia Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation186.3 M177.4 M51.1 M
Slightly volatile
Depreciation12.4 M11.8 M4.6 M
Slightly volatile
Capital Expenditures12.7 M6.6 M8.7 M
Slightly volatile
Total Cash From Financing Activities252.4 M213.6 M180.4 M
Slightly volatile
End Period Cash Flow208.9 M233.2 M152.4 M
Slightly volatile
Change To Netincome207.4 M197.6 M64.1 M
Slightly volatile
Begin Period Cash Flow207 M276.4 M142 M
Slightly volatile
Issuance Of Capital Stock379.7 M203.4 M190 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio17.0317.9256.7114
Very volatile
PTB Ratio1.441.5211.0621
Slightly volatile
Days Sales Outstanding76.9748.3481.7254
Pretty Stable
Book Value Per Share6.697.946.4404
Slightly volatile
Stock Based Compensation To Revenue2.522.41.059
Slightly volatile
Capex To Depreciation0.610.6528.8956
Slightly volatile
PB Ratio1.441.5211.0621
Slightly volatile
EV To Sales17.3418.2549.6
Very volatile
Payables Turnover0.770.819.901
Slightly volatile
Sales General And Administrative To Revenue1.241.961.5033
Slightly volatile
Research And Ddevelopement To Revenue3.967.254.1129
Slightly volatile
Capex To Revenue0.08540.08980.3465
Slightly volatile
Cash Per Share6.465.486.1568
Slightly volatile
Days Payables Outstanding489466171
Slightly volatile
Current Ratio6.395.26.8659
Slightly volatile
Tangible Book Value Per Share6.697.946.4404
Slightly volatile
Receivables Turnover7.176.127.8287
Pretty Stable
Shareholders Equity Per Share6.697.946.4404
Slightly volatile
Debt To Equity0.230.220.102
Slightly volatile
Capex Per Share0.050.05260.1421
Pretty Stable
Graham Net Net4.742.634.4207
Slightly volatile
Revenue Per Share0.50.530.5339
Slightly volatile
Interest Debt Per Share0.971.910.8023
Slightly volatile
Debt To Assets0.170.160.0792
Slightly volatile
Operating Cycle76.9748.3481.7254
Pretty Stable
Price Book Value Ratio1.441.5211.0621
Slightly volatile
Days Of Payables Outstanding489466171
Slightly volatile
Ebt Per Ebit1.261.121.518
Slightly volatile
Effective Tax Rate0.06040.06790.0741
Slightly volatile
Company Equity Multiplier1.421.571.3414
Pretty Stable
Total Debt To Capitalization0.180.170.089
Slightly volatile
Debt Equity Ratio0.230.220.102
Slightly volatile
Quick Ratio6.395.26.8659
Slightly volatile
Net Income Per E B T0.740.830.9081
Slightly volatile
Cash Ratio1.861.963.8765
Slightly volatile
Days Of Sales Outstanding76.9748.3481.7254
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.311.171.1782
Very volatile
Price To Book Ratio1.441.5211.0621
Slightly volatile
Fixed Asset Turnover0.260.271.3126
Slightly volatile
Debt Ratio0.170.160.0792
Slightly volatile
Price Sales Ratio17.0317.9256.7114
Very volatile
Asset Turnover0.07010.05590.0665
Slightly volatile
Price Fair Value1.441.5211.0621
Slightly volatile

Intellia Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap181.9 M204.6 M223.3 M
Slightly volatile
Enterprise Value174 M195.8 M213.7 M
Slightly volatile

Intellia Fundamental Market Drivers

Intellia Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Intellia Therapeutics Financial Statements

Intellia Therapeutics stakeholders use historical fundamental indicators, such as Intellia Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Intellia Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Intellia Therapeutics' assets and liabilities are reflected in the revenues and expenses on Intellia Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Intellia Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue23.8 M28.7 M
Total Revenue66.6 M35.9 M
Cost Of Revenue9.3 M8.8 M
Stock Based Compensation To Revenue 2.40  2.52 
Sales General And Administrative To Revenue 1.96  1.24 
Research And Ddevelopement To Revenue 7.25  3.96 
Capex To Revenue 0.09  0.09 
Revenue Per Share 0.53  0.50 
Ebit Per Revenue(10.62)(11.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
WDWalker Dunlop
GMGeneral Motors
GMGeneral Motors
When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:
How To Invest In Intellia
Details
Is Intellia Stock a good investment?
Details
What is Intellia Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Intellia Therapeutics Correlation against competitors.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. Anticipated expansion of Intellia directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Intellia Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(4.25)
Revenue Per Share
0.549
Quarterly Revenue Growth
0.513
Return On Assets
(0.29)
Return On Equity
(0.52)
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Intellia Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Intellia Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Intellia Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY